Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Apexigen
|
| gptkbp:ceo |
Jaime E. Echeverri
|
| gptkbp:clinical_trial |
AL X148
AL X196 |
| gptkbp:collaborations |
gptkb:Merck_&_Co.
|
| gptkbp:focus |
cancer therapies
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alx Oncology
|
| gptkbp:investment |
Venture capital firms
|
| gptkbp:language_of_instruction |
AL X148 for solid tumors
AL X196 for hematologic malignancies |
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:research_focus |
immune-oncology
|
| gptkbp:symbol |
ALXO
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.alxoncology.com
|
| gptkbp:bfsParent |
gptkb:ALX-0701
gptkb:ALX-0736 |
| gptkbp:bfsLayer |
5
|